Share

Phathom Pharmaceuticals Inc. - news published 211 - readings 3.102

BACK
Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PHATHOM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-4151574 (State or Other Jurisdiction of Inco ...

Continue reading
06.03.2025
Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our curren ...

Continue reading
06.03.2025
Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Form 8-K)

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • VOQUEZNA ® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3 • Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, a ...

Continue reading
06.03.2025